David E Sterner
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$2.6MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $2.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 5, 2021 | NIH | SBIR Phase I Novel TXNIP degraders for treating diabetes | $266K | PROGENRA INC |
| Sep 10, 2019 | NIH | SBIR Phase I Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway | $225K | PROGENRA INC |
| Jul 21, 2016 | NIH | SBIR Phase I A novel mechanism based therapy for cystic fibrosis | $205K | PROGENRA INC |
| Aug 6, 2015 | NIH | SBIR Phase II Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol | $612K | PROGENRA INC |
| Jul 20, 2015 | NIH | SBIR Phase II Novel molecular therapeutics for cystic fibrosis | $667K | PROGENRA INC |
| Apr 22, 2015 | NIH | SBIR Phase II Ubiquitin E3 ligase detection by fluorescence resonance transfer | $611K | PROGENRA INC |
Peer ranks
Federal funding#732
Awards as PI#315
Patents#273
Companies
- PROGENRA INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.